Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for disorders of the nervous system,...
-
SAN FRANCISCO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today...
-
Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy
-
Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
-
Neurona Therapeutics Presents Positive Clinical Data Update from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at American Academy of Neurology A
-
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline
-
Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meet
-
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
-
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
-
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference